Vyluma, which recently spun off from Nevakar, has a robust pipeline for potential therapies addressing refractive error. Navneet Puri, PhD, the company’s founder, chairman, and CEO, offers additional insights.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.